Riskpilot← Back to searchSign inGet full accessMelius Pharma AB
ABActiveOrg 5593323669Rönninge Skolväg 9 BResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
-21% vs 2023
Equity ratio
66.8%
Financial strength
Net profit 2024
SEK -12,7M
-21% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -12,7M | -21% |
| Net profit | SEK -12,7M | -21% |
| Total assets | SEK 3,1M | -40% |
| Equity | SEK 2,1M | -46% |
| Employees | 0 | — |
Legal name
Melius Pharma AB
Org number
5593323669
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30 augusti 2021
Share capital
SEK 1 114 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Läkemedelsutveckling och licensiering av intellektuella tillgångar såsom patent och reslultat från kliniska studier.
Address
Rönninge Skolväg 9 B
Email
mark.kornfeld@meliuspharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 37 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −4 330 | −10 503 | −12 694 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −4 330 | −10 503 | −12 694 |
| Net financials | — | 11 | −66 |
| Profit before tax | −4 330 | −10 492 | −12 727 |
| Tax | −0 | −0 | −0 |
| Net profit | −4 330 | −10 492 | −12 727 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 17 892 | 5 178 | 3 092 |
| Equity | 14 217 | 3 794 | 2 066 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 3 675 | 1 385 | 1 026 |
| Total debt | 3 675 | 1 385 | 1 026 |
EBITDA margin
-1269400000.0%
This company
15.8%
Market median
-8034177315% vs market
20222024
Equity ratio
66.8%
This company
38.2%
Market median
+75% vs market
20222024
Return on equity
-616.0%
This company
18.4%
Market median
-3448% vs market
20222024
Net profit margin
-1272700000.0%
This company
8.1%
Market median
-15712345779% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.50×
This company
0.62×
Market median
+19% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-08-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LJ Audit | Audit | 2024 | — | — |
ME Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
MR Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Melius Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Johan Rudengren | Audit | 0 companies |
| Mark Ernest Kornfeld | Chief Executive Officer | 0 companies |
| Magnus Rolf Hahnsjö | Audit | 0 companies |
| Niels Skjaerbaek | Board of Directors | 0 companies |
| Lars Christer Fredrik Fåhraeus | Board of Directors | 0 companies |
| Peter Heinrich | Chairman | 0 companies |
| Thomas Emanuel Bergh | Board of Directors | 0 companies |
| Snickar Karl Johan Tobieson | Board of Directors | 0 companies |
| Linus Johannes Wiebe | Board of Directors | 0 companies |
| Christine Lemke | Board of Directors | 0 companies |
| John Bondo Hansen | Board of Directors | 0 companies |
| Bert Roland Kari Junno | Chairman | 0 companies |